Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 904-907

  Flatt, Brenton ^a   Martin, Richard ^a   Wang, Tie Lin ^a   Mahaney, Paige ^c   Murphy, Brett ^a   Gu, Xiao Hui ^a   Foster, Paul ^a   Li, Jiali ^a   Pircher, Parinaz ^a   Petrowski, Mary ^a   Schulman, Ira ^a   Westin, Stefan ^a   Wrobel, Jay ^b   Yan, Grace ^a   Bischoff, Eric ^a   Daige, Chris ^a   Mohan, Raju ^a  

^a EXELIXIS INC   (United States)

^b PFIZER INC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6 ALPHA ETHYL CHENODEOXYCHOLILC ACID; AZEPINO[4,5 B]INDOLE; CHOLESTEROL; FARNESOID X RECEPTOR; INDOLE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WAY 362450; XL 335;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; MOUSE; MOUSE STRAIN; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; AZEPINES; CHOLESTEROL; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG DISCOVERY; INDOLES; MICE; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 64349115048     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8014124     Document Type: Article

References (29)

1. Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.; Perlmann, T.; Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W. W.; Evans, R. M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81, 687-693.
2. Seol, W.; Choi, H. S.; Moore, D. D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 1995, 9, 72-85.
3. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schuetz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade. Cell 1995, 83, 835-839.
4. Nuclear Receptor Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97, 161 - 163.
5. Lee, F. Y.; Lee, H.; Hubbert, M. L.; Edwards, P.A. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 2006, 31, 572-580.
6. Sinal, C. J.; Tohkin, M.; Miyata, M.; Ward, J. M.; Lambert, G.; Gonzalez, F. J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102, 731-744.
7. Zhang, Y; Edwards, P. FXR signaling in metabolic disease. FEBS Lett. 2008, 582, 10-18.
8. Edwards, P. A.; Kast, H. R.; Anisfeld, A. M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 2002, 43, 2-12.
9. Kalaany, N. Y.; Mangelsdorf, D. J. LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 2006, 68, 159-191.
10. (a) Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids. Science 1999, 284, 1362-1365.
11. (b) Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284, 1365-1368.
12. (c)Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3, 543-553.
13. Modica, S.; Moschetta, A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett. 2006, 580, 5492-5499.
14. Watanabe, M.; Houten, S. M.; Mataki, C.; Christoffolete, M. A.; Kim, B. W.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O. T.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439, 484-489.
15. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T. M. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 2000, 43, 2971-2974.
16. Nicolaou, K. C.; Evans, R. M.; Roecker, A. J.; Hughes, R.; Downes, M.; Pfefferkorn, J. A. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 2003, 1, 908-920.
17. (a) Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Constantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 2002, 45, 3569-3572.
18. (b) Charles, T.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discovery 2008, 7, 678-693.
19. Compound 6m (XL335) has also been presented as WAY-362450 (FXR-450): Indoleazepines as a New Class of Nonsteroidal Agonists of the Farnesoid X Receptor: Identification of WAY-362450 (FXR- 450) as a Clinical Candidate for the Treatment of Dyslipidemia. Abstracts of Papers, 235th National Meeting of the American Chemical Society, New Orleans, LA, Apr 6-10, 2008; American Chemical Society: Washington, DC, 2008.
20. Martin, R.; Wang, T.-L.; Flatt, B. T.; Gu, X.-H.; Griffith, R. Azepinoindole and Pyridoindole Derivatives As Pharmaceutical Agents. U.S. Patent Application US 20040023947, 2004.
21. (a) Kuehne, M. E.; Bohnert, J. C.; Bornmann, W. G.; Kirkemo, C. L.; Kuehne, S. E.; Seaton, P. J.; Zebovitz, T. C. Biomimetic syntheses of indole alkaloids. Syntheses of β-carboline and indoloazepine intermediates. J. Org. Chem. 1985, 50, 919-924.
22. (b) Kuehne et al. propose that the rearrangement of carbolines to the corresponding azepino[4,5- b]indoles occurs via intramolecular N-alkylation followed by opening of the resulting aziridine.
23. (a) Sinal, C. J.; Tohkin, M.; Miyata, M.; Ward, J. M.; Lambert, G.; Gonzales, F. J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102, 731-744.
24. (b) Lu, T. T.; Makishima, M.; Repa, J. J.; Schoonjans, K.; Kerr, T. A.; Auwerx, J.; Mangelsdorf, D. J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6, 507-515.
25. (a) Goodwin, B.; Jones, S. A.; Price, R. R.; Watson, M. A.; McKee, D. D.; Moore, L. B.; Galardi, C.; Wilson, J. G.; Lewis, M. C.; Roth, M. E.; Maloney, P. R.; Willson, T. M.; Kliewer, S. A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6, 517-526.
26. (b) Watanabe, M.; Houten, S. M.; Wang, L.; Moschetta, A.; Mangelsdorf, D. J.; Heyman, R. A.; Moore, D. D.; Auwerx, J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 2004, 113, 1408-1418.
27. Grober, J.; Zaghini, I.; Fujii, H.; Jones, S. A.; Kliewer, S. A.; Willson, T. M.; Ono, T.; Besnard, P. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. J. Biol. Chem. 1999, 274, 29749-29754.
28. Li, J.; Pircher, P. C.; Schulman, I. G.; Westin, S. K. Regulation of complement C3 expression by the bile acid receptor FXR. J. Biol. Chem. 2005, 280, 7427-7434.
29. Ananthanarayanan, M.; Balasubramanian, N.; Makishima, M.; Mangelsdorf, D. J.; Suchy, F. J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 2001, 276, 28857-28865.